Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Large tubular colonic mass with hematochezia and altered bowel habits. Lipoma.

American family physician·2012

Same author

Large serrated tongue and gastrointestinal bleeding. Symptomatic gastric amyloidosis (SGA).

Gut·2010

Same author

Helicobacter pylori and gastric cancer: a marital risk?

Southern medical journal·2009

Same author

Asymptomatic esophageal perforation after foreign body ingestion.

Gastrointestinal endoscopy·2005

Same author

A large biloma causing gastric outlet obstruction after a percutaneous liver biopsy.

Journal of clinical gastroenterology·2004

Same author

Alcoholic foamy degeneration and a markedly elevated GGT: a case report and literature review.

Digestive diseases and sciences·2003

Search research articles

Related Experiment Video

Updated: May 21, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Immunotherapy in inflammatory bowel disease.

Jatinder P Ahluwalia¹

¹Gastroenterology Clinic of Acadiana and Lafayette General Medical Center, Lafayette, LA, USA. jpahluwalia@yahoo.com

The Medical Clinics of North America

|June 19, 2012

Summary

Novel immunologic agents targeting TNF-alpha and alpha4-integrin offer new treatments for inflammatory bowel disease (IBD). This review examines the efficacy, risks, and challenges of these therapies for Crohn disease and ulcerative colitis.

More Related Videos

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4⁺ T Cells to Immunodeficient Mice

Published on: December 16, 2021

Related Experiment Videos

Last Updated: May 21, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4⁺ T Cells to Immunodeficient Mice

Published on: December 16, 2021

Area of Science:

Gastroenterology and Immunology
Molecular and Cellular Biology

Background:

Inflammatory bowel disease (IBD) prevalence is rising globally, causing substantial patient morbidity.
Immune system dysregulation, marked by elevated proinflammatory cytokines and mucosal vascular adhesion molecules, is key to IBD pathogenesis.

Purpose of the Study:

To discuss the efficacy of current immunologic agents for Crohn disease and ulcerative colitis.
To review the associated risks and challenges of these novel IBD therapies.

Main Methods:

Review of approved immunologic agents targeting TNF-alpha and alpha4-integrin.
Analysis of clinical data on efficacy, safety, and patient outcomes.

Main Results:

Immunologic agents targeting TNF-alpha and alpha4-integrin have demonstrated efficacy in treating IBD.
These therapies present specific risks and challenges that require careful patient management.

Conclusions:

Targeted immunotherapies represent significant advancements in IBD treatment.
Ongoing research and careful clinical application are essential to optimize outcomes and mitigate risks.